Newsletter

Click here to join
our newsletter.

Patient Contact

We are looking for participants.


We at Immutep are passionate to research and develop new opportunities in cancer to increase the patient’s life. Our lead product, eftilagimod alpha (LAG-3Ig or IMP321) is currently under clinical development in 2 clinical studies to determine the safety, tolerability and efficacy of the product.

Participation in our clinical trials is always based on the patient’s own decision. For further information, please contact your treating physician.

Our current trials:

AIPAC (Active Immunotherapy PAClitaxel)

Active Immunotherapy PAClitaxel (AIPAC) is a Phase II b clinical trial in metastatic breast cancer (MBC) based on our LAG-3 technology by combining taxane-based chemotherapy called paclitaxel and with eftilagimod alpha (LAG-3Ig or IMP321) as an immunotherapy. This combination is aimed to boost the immune response against tumour cells compared to chemotherapy alone. In AIPAC, 226 hormone receptor positive metastatic breast cancer patients are randomized 1:1 to treatment A (Paclitaxel chemotherapy plus Placebo) or treatment B (Paclitaxel chemotherapy plus eftilagimod alpha i). Thereafter, patients will pass over to the maintenance phase.

This study is ongoing in seven European countries.
Contact details can be found here: https://clinicaltrials.gov/ct2/show/NCT02614833

TACTI-mel (Two ACTive Immunotherapeutics in melanoma)

Two ACTive Immunotherapeutics in melanoma (TACTI-mel) is a Phase I safety and dose finding combination clinical trial of Eftilagimod alpha together with pembrolizumab (PD-1 blocking antibody also known as Keytruda). The study is based on the combination of two immunotherapy to enhance the immune response by activated T cells. TACTI-mel will enroll up to 18 patients with locally advanced (unresectable Stage III) or metastatic (Stage IV) melanoma with ascending subcutaneous doses of eftilagimod alpha up to 30 mg per injection.

Patients having a suboptimal response or having had disease progression with pembrolizumab monotherapy are eligible for the study and will receive the combination of pembrolizumab plus eftilagimod alpha.

This study is ongoing in Australia.
Contact details can be found here: https://clinicaltrials.gov/ct2/show/NCT02676869